Synonym
AZD-7806; AZD 7806; AZD7806; A 3309; A3309; A-3309; AJG-533; Elobixibat
IUPAC/Chemical Name
(R)-(2-(2-((3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydrobenzo[b][1,4]thiazepin-8-yl)oxy)acetamido)-2-phenylacetyl)glycine
InChi Key
XFLQIRAKKLNXRQ-UUWRZZSWSA-N
InChi Code
InChI=1S/C36H45N3O7S2/c1-4-6-18-36(19-7-5-2)24-39(27-16-12-9-13-17-27)28-20-30(47-3)29(21-31(28)48(44,45)25-36)46-23-32(40)38-34(26-14-10-8-11-15-26)35(43)37-22-33(41)42/h8-17,20-21,34H,4-7,18-19,22-25H2,1-3H3,(H,37,43)(H,38,40)(H,41,42)/t34-/m1/s1
SMILES Code
O=C(O)CNC([C@@H](C1=CC=CC=C1)NC(COC2=C(SC)C=C(C3=C2)N(C4=CC=CC=C4)CC(CCCC)(CCCC)CS3(=O)=O)=O)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
695.89
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Quigley EM, Neshatian L. Advancing treatment options for chronic idiopathic constipation. Expert Opin Pharmacother. 2015 Dec 23:1-11. [Epub ahead of print] PubMed PMID: 26630260.
2: Jiang C, Xu Q, Wen X, Sun H. Current developments in pharmacological therapeutics for chronic constipation. Acta Pharm Sin B. 2015 Jul;5(4):300-9. doi: 10.1016/j.apsb.2015.05.006. Epub 2015 Jun 6. Review. PubMed PMID: 26579459; PubMed Central PMCID: PMC4629408.
3: Nusrat S, Miner PB Jr. New pharmacological treatment options for irritable bowel syndrome with constipation. Expert Opin Emerg Drugs. 2015 Dec;20(4):625-36. doi: 10.1517/14728214.2015.1105215. Epub 2015 Nov 7. PubMed PMID: 26548544.
4: Davis M, Gamier P. New Options in Constipation Management. Curr Oncol Rep. 2015 Dec;17(12):55. doi: 10.1007/s11912-015-0481-x. PubMed PMID: 26449843.
5: Rudling M, Camilleri M, Graffner H, Holst JJ, Rikner L. Specific inhibition of bile acid transport alters plasma lipids and GLP-1. BMC Cardiovasc Disord. 2015 Jul 22;15:75. doi: 10.1186/s12872-015-0070-9. PubMed PMID: 26197999; PubMed Central PMCID: PMC4511433.
6: Thomas RH, Luthin DR. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents. Pharmacotherapy. 2015 Jun;35(6):613-30. doi: 10.1002/phar.1594. Epub 2015 May 27. Review. PubMed PMID: 26016701.
7: Acosta A, Camilleri M. Elobixibat and its potential role in chronic idiopathic constipation. Therap Adv Gastroenterol. 2014 Jul;7(4):167-75. doi: 10.1177/1756283X14528269. Review. PubMed PMID: 25057297; PubMed Central PMCID: PMC4107709.
8: Mozaffari S, Didari T, Nikfar S, Abdollahi M. Phase II drugs under clinical investigation for the treatment of chronic constipation. Expert Opin Investig Drugs. 2014 Nov;23(11):1485-97. doi: 10.1517/13543784.2014.932770. Epub 2014 Jun 24. Review. PubMed PMID: 24960333.
9: Appleby RN, Walters JR. The role of bile acids in functional GI disorders. Neurogastroenterol Motil. 2014 Aug;26(8):1057-69. doi: 10.1111/nmo.12370. Epub 2014 Jun 5. Review. PubMed PMID: 24898156.
10: Corsetti M, Tack J. New pharmacological treatment options for chronic constipation. Expert Opin Pharmacother. 2014 May;15(7):927-41. doi: 10.1517/14656566.2014.900543. Epub 2014 Mar 24. Review. PubMed PMID: 24661106.
11: Wong BS, Camilleri M. Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013 Feb;22(2):277-84. doi: 10.1517/13543784.2013.753056. Epub 2012 Dec 8. Review. PubMed PMID: 23215781.
12: Gras B, Magge S, Bloom A, Lembo A. Motility disorders of the colon and rectum. Curr Opin Gastroenterol. 2013 Jan;29(1):66-71. doi: 10.1097/MOG.0b013e32835a80e7. Review. PubMed PMID: 23207598.
13: Zinsmeister AR, Burton D, Camilleri M. Pharmacodynamic and clinical endpoints for functional colonic disorders: statistical considerations. Dig Dis Sci. 2013 Feb;58(2):509-18. doi: 10.1007/s10620-012-2369-z. Epub 2012 Aug 24. PubMed PMID: 22918691; PubMed Central PMCID: PMC3529760.
